Main page content

Displaying results 1 - 7 of 7
Publication ID: PEP24-03-001
Published:
SAMHSA’s updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. The toolkit also emphasizes that harm reduction and access to treatment are essential aspects of overdose prevention.
Publication ID: PEP23-03-00-001
Published:
SAMHSA’s updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. The toolkit also emphasizes that harm reduction and access to treatment are essential aspects of overdose prevention.
Publication ID: PEP21-06-01-002
Published:

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

Publication ID: PEP21-06-02-002
Published:

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

Publication ID: PEP21-PL-Guide-5
Published:

This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.

Publication ID: SMA18-5071
Published:

This series of four fact sheets emphasizes the importance of continuing a mother's treatment for opioid use disorder (OUD) throughout pregnancy. The series includes information on OUD and pregnancy, OUD treatment, neonatal abstinence syndrome, and considerations to address before hospital discharge.

Publication ID: SMA14-4852
Published:

This guide highlights the use of medication-assisted treatment (MAT) for opioid use disorder in drug courts. It reviews effective medications, including methadone, buprenorphine, and naltrexone. The guide also provides strategies to increase the use of MAT in drug court programs.